Table 1.
Number of designated features captured among each OASIS method’s 1000 most significant results
| Feature | Data | LMS | LMS | LOO | LOO | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cohort | Category | Type | MIST | MAST | DIP | SIBER | SST | MOP | SST | MOP |
| 14 AMKLs | TSG | SX | 386 | 112 | 108 | 6 | 269 | 117 | 27 | 73 |
| 14 AMKLs | TSG | SJ | 326 | 104 | 165 | 97 | 310 | 116 | 112 | 97 |
| 14 AMKLs | TSG | AX | 340 | 247 | 406 | 271 | 204 | 129 | 146 | 119 |
| 14 AMKLs | TSG | AG | 174 | 125 | 155 | 136 | 107 | 87 | 60 | 61 |
| 14 AMKLs | GDR | SX | 319 | 221 | 229 | 27 | 351 | 2 | 0 | 0 |
| 14 AMKLs | GDR | SJ | 122 | 73 | 84 | 3 | 151 | 2 | 3 | 1 |
| 14 AMKLs | GDR | AX | 46 | 25 | 59 | 40 | 11 | 4 | 1 | 0 |
| 14 AMKLs | GDR | AG | 4 | 3 | 6 | 5 | 3 | 0 | 0 | 0 |
| 14 AMKLs | TOL | SX | 0 | 8 | 0 | 0 | 4 | 1 | 2 | 2 |
| 14 AMKLs | TOL | SJ | 0 | 1 | 1 | 3 | 3 | 1 | 2 | 0 |
| 14 AMKLs | TOL | AX | 3 | 7 | 0 | 3 | 1 | 1 | 3 | 2 |
| 14 AMKLs | TOL | AG | 4 | 4 | 0 | 3 | 3 | 0 | 2 | 2 |
| 157 AMLs | TSG | SX | 325 | 318 | 294 | 269 | 365 | 350 | 251 | 316 |
| 157 AMLs | TSG | SJ | 354 | 374 | 340 | 326 | 406 | 347 | 341 | 337 |
| 157 AMLs | GDR | SX | 46 | 4 | 38 | 40 | 7 | 2 | 0 | 0 |
| 157 AMLs | GDR | SJ | 36 | 0 | 20 | 11 | 13 | 1 | 0 | 3 |
Note: For each row, the greatest number is shown in boldface. *TSG = tumor subgroup; GDR = gender; TOL = tumor outlier; SX = sequence exons; SJ = sequence junctions; AX = array exons; AG = array genes.